Coherus Content With Dual Pipeline Strategy

US Firm Reveals Full-Year Udenyca Biosimilar Sales

Coherus BioSciences sees value in having both wholly-owned and in-licensed biosimilar assets, as the firm gears up to have a portfolio of at least six products within five years.

Road_Mountain
Coherus is finally in year-end profit after launching its first product • Source: Shutterstock

Coherus BioSciences aims to continue balancing internally-developed biosimilars with in-licensed product opportunities, as the US-based player enters its 2020 financial year cash flow positive from operations following a virtual full year of wholly-owned Udenyca (pegfilgrastim-cbqv) sales.

Denny Lanfear, Coherus’ president, CEO and chairman, told investors at the company’s year-end financial results call, “I think that it's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By 

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By 

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.

Who’s Hired? Stada Picks Biogen’s Biosimilars Chief Henshaw To Lead Specialty Segment

 
• By 

Stada has appointed former Biogen biosimilars head Ian Henshaw as the new leader of its Specialty segment. Meanwhile, Craig Burton has left the AAM for Fresenius Kabi, Australia's GBMA is looking for a new chief executive, and Speranza, Outlook and EuroAPI have announced new appointments.

Three’s A Crowd? Celltrion Launches Denosumab In US

 
• By 

A third pair of Prolia and Xgeva rivals has now been launched in the US, with Celltrion throwing its hat into the ring after denosumab launches by Sandoz and Fresenius Kabi. But this is only the beginning for what is shaping up to be another highly competitive biosimilars market.

More from Business

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 

Collating data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By 

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

Bio Usawa To Market Formycon’s Lucentis Biosimilar In Sub-Saharan Africa

 

Bio Usawa’s CEO said access to advanced biologics should not be a privilege of geography or income, as it prepares to launch Formycon/Bioeq’s ranibizumab biosimilar in Africa.